- Home
- ESPR vs ORIC Comparison
ESPR vs ORIC Comparison
Compare ESPR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- ORIC
- Stock Information
- Founded
- ESPR 2008
- ORIC 2014
- Country
- ESPR United States
- ORIC United States
- Employees
- ESPR N/A
- ORIC N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- ORIC Health Care
- Exchange
- ESPR Nasdaq
- ORIC Nasdaq
- Market Cap
- ESPR 305.0M
- ORIC 362.9M
- IPO Year
- ESPR 2013
- ORIC 2020
- Fundamental
- Price
- ESPR $0.80
- ORIC $5.08
- Analyst Decision
- ESPR Buy
- ORIC Strong Buy
- Analyst Count
- ESPR 7
- ORIC 8
- Target Price
- ESPR $5.93
- ORIC $18.83
- AVG Volume (30 Days)
- ESPR 5.1M
- ORIC 630.2K
- Earning Date
- ESPR 05-06-2025
- ORIC 05-05-2025
- Dividend Yield
- ESPR N/A
- ORIC N/A
- EPS Growth
- ESPR N/A
- ORIC N/A
- EPS
- ESPR N/A
- ORIC N/A
- Revenue
- ESPR $259,574,000.00
- ORIC N/A
- Revenue This Year
- ESPR $5.70
- ORIC N/A
- Revenue Next Year
- ESPR N/A
- ORIC N/A
- P/E Ratio
- ESPR N/A
- ORIC N/A
- Revenue Growth
- ESPR 12.99
- ORIC N/A
- 52 Week Low
- ESPR $0.82
- ORIC $3.90
- 52 Week High
- ESPR $3.94
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- ESPR 32.43
- ORIC 44.71
- Support Level
- ESPR $0.93
- ORIC $4.52
- Resistance Level
- ESPR $1.11
- ORIC $5.83
- Average True Range (ATR)
- ESPR 0.11
- ORIC 0.52
- MACD
- ESPR 0.01
- ORIC 0.07
- Stochastic Oscillator
- ESPR 17.93
- ORIC 40.58
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.